Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in Recurrent or Refractory Central Nervous System Lymphoma (CNSL)
NCT04906902Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2021
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in central nervous system lymphoma, sponsored by Dana-Farber Cancer Institute. Started Aug 2021; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on NCT04906902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04906902.